Studies on Immunization Against Plague VIII. Study of Three Immunizing Preparations in Protecting Primates Against Pneumonic Plague

Nj, Ehrenkranz; Kf, Meyer

doi:10.1093/infdis/96.2.138

Cited by 34 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One version of the formalin-killed vaccine, designated the "plague vaccine, USP," was widely used by U.S. military personnel during the Vietnam War, where evidence suggests that it was significantly less reactogenic than Haffkine's heat-killed vaccine yet still protected against bubonic plague (24). However, animal studies indicate that formalin-killed vaccines do not protect well against pulmonary Y. pestis infection (2,10,15), and humans vaccinated with formalin-killed vaccines have contracted pneumonic plague (9,25,39).…”

mentioning

confidence: 99%

Cell-Mediated Protection against PulmonaryYersinia pestisInfection

et al. 2005

View full text Add to dashboard Cite

Pulmonary infection with the bacterium Yersinia pestis causes pneumonic plague, an often-fatal disease for which no vaccine is presently available. Antibody-mediated humoral immunity can protect mice against pulmonary Y. pestis infection, an experimental model of pneumonic plague. Little is known about the protective efficacy of cellular immunity. We investigated the cellular immune response to Y. pestis in B-cell-deficient MT mice, which lack the capacity to generate antibody responses. To effectively prime pulmonary cellular immunity, we intranasally vaccinated MT mice with live replicating Y. pestis. Vaccination dramatically increased survival of MT mice challenged intranasally with a lethal Y. pestis dose and significantly reduced bacterial growth in pulmonary, splenic, and hepatic tissues. Vaccination also increased numbers of pulmonary T cells, and administration of T-cell-depleting monoclonal antibodies at the time of challenge abrogated vaccineinduced survival. Moreover, the transfer of Y. pestis-primed T cells to naive MT mice protected against lethal intranasal challenge. These findings establish that vaccine-primed cellular immunity can protect against pulmonary Y. pestis infection and suggest that vaccines promoting both humoral and cellular immunity will most effectively combat pneumonic plague.

show abstract

mentioning

confidence: 99%

Cell-Mediated Protection against PulmonaryYersinia pestisInfection

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In fact, owing to reports of the reactogenicity and inefficacy of whole killed-cell vaccines against pneumonic plague, the previously licensed plague vaccine USP containing iYp was discontinued in the United States. In contrast, other studies have provided evidence that iYp can protect against pneumonic plague (3,9,38,39). These latter studies were performed using parenteral administration of iYp, and only one study reported protection by administering iYp in s.c. prime-i.n.…”

Section: Discussionmentioning

confidence: 99%

“…However, two studies have reported that protection against pneumonic plague can be induced in experimental animals using inactivated Y. pestis (iYp). In the first study by Ehrenkranz and Meyer (9), extremely high doses of killed Y. pestis strain Yerka delivered multiple times subcutaneously (s.c.) or intramuscularly (i.m.) were found to protect rhesus monkeys from intratracheal (i.t.)…”

mentioning

confidence: 99%

Intranasal Administration of an Inactivated Yersinia pestis Vaccine with Interleukin-12 Generates Protective Immunity against Pneumonic Plague

Kumar

Kirimanjeswara

Metzger

2011

Clin Vaccine Immunol

View full text Add to dashboard Cite

Inhalation of Yersinia pestis causes pneumonic plague, which rapidly progresses to death. A previously licensed killed whole-cell vaccine is presently unavailable due to its reactogenicity and inconclusive evidence of efficacy. The present study now shows that vaccination intranasally (i.n.) with inactivated Y. pestis CO92 (iYp) adjuvanted with interleukin-12 (IL-12) followed by an i.n. challenge with a lethal dose of Y. pestis CO92 prevented bacterial colonization and protected 100% of mice from pneumonic plague. Survival of the vaccinated mice correlated with levels of systemic and lung antibodies, reduced pulmonary pathology and proinflammatory cytokines, and the presence of lung lymphoid cell aggregates. Protection against pneumonic plague was partially dependent upon Fc receptors and could be transferred to naïve mice with immune mouse serum. On the other hand, protection was not dependent upon complement, and following vaccination, depletion of CD4 and/or CD8 T cells before challenge did not affect survival. In summary, the results demonstrate the safety, immunogenicity, and protective efficacy of i.n. administered iYp plus IL-12 in a mouse model of pneumonic plague.

show abstract

“…F1 specific antibodies produced in rabbits, agglutinated plague bacilli and passively protected mice and rats following subcutaneous challenge with virulent Y. pestis (Baker et al, 1952). Passive transfer of F1-specific antibodies also protected macaques against pneumonic plague (Ehrenkranz and Meyer, 1955). Subsequently, vaccination with recombinant F1 was shown to protect mice against aerosolized Y. pestis (Andrews et al, 1996).…”

Section: Subunit Vaccines Based On the F1 Lcrv And Yscf Proteinsmentioning

confidence: 99%